2000 |
Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. November 2000;27(5):687-694. |
104 |
92 |
2020 |
Rokidi S, Bravenboer N, Gamsjaeger S, Misof B, Blouin S, Chavassieux P, Klaushofer K, Paschalis E, Papapoulos S, Appelman-Dijkstra N. Impact microindentation assesses subperiosteal bone material properties in humans. Bone. February 2020;131:115110. |
4 |
3 |
2020 |
Rokidi S, Bravenboer N, Gamsjaeger S, Chavassieux P, Zwerina J, Paschalis E, Papapoulos S, Appelman-Dijkstra N. Impact microindentation measurements correlate with cortical bone material properties measured by Fourier transform infrared imaging in humans. Bone. August 2020;137:115437. |
0 |
0 |
2021 |
Jensen PR, Andersen TL, Chavassieux P, Roux J-P, Delaisse J-M. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone. April 2021;145:115850. |
5 |
2 |
2022 |
Borggaard XG, Roux J-P, Delaisse J-M, Chavassieux P, Andreasen CM, Andersen TL. Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling. Bone. July 2022;160:116419. |
1 |
0 |
2007 |
Chapurlat RD, Arlot M, Burt‐Pichat B, Chavassieux P, Roux JP, Portero‐Muzy N, Delmas PD. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long‐term bisphosphonates: a bone biopsy study. J Bone Miner Res. October 2007;22(10):1502-1509. |
19 |
16 |
2020 |
Dubail J, Brunelle P, Baujat G, Huber C, Doyard M, Michot C, Chavassieux P, Khairouni A, Topouchian V, Monnot S, Koumakis E, Cormier‐Daire V. Homozygous loss‐of‐function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta. J Bone Miner Res. August 2020;35(8):1470-1480. |
2 |
2 |
2021 |
Farlay D, Rizzo S, Ste-Marie L-G, Michou L, Morin SN, Qiu S, Chavassieux P, Chapurlat RD, Rao SD, Brown JP, Boivin G. Duration-dependent increase of human bone matrix mineralization in long-term bisphosphonate users with atypical femur fracture. J Bone Miner Res. June 2021;36(6):1031-1041. |
2 |
1 |
2022 |
Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res. January 2022;37(1):36-40. |
2 |
2 |
1997 |
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. September 15, 1997;100(6):1475-1480. |
63 |
56 |